Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

Ian C. Marschner, Ann C. Collier, Robert W. Coombs, Richard T. D'Aquila, Victor DeGruttola, Margaret A Fischl, Scott M. Hammer, Michael D. Hughes, Victoria A. Johnson, David A. Katzenstein, Douglas D. Richman, Laura M. Smeaton, Stephen A. Spector, Michael S. Saag

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions in plasma HIV-1 RNA levels. The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy. Pretherapy HIV-1 RNA levels were prognostic independently of on-therapy levels. In addition, the reduction in risk associated with any given reduction of the level of HIV-1 RNA did not vary by pretherapy level. Having either a reduction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a delay in clinical disease progression. This indicates that patient prognosis should be assessed using both HIV-1 RNA and CD4+ lymphocyte responses to therapy.

Original languageEnglish
Pages (from-to)40-47
Number of pages8
JournalJournal of Infectious Diseases
Volume177
Issue number1
StatePublished - Jan 21 1998
Externally publishedYes

Fingerprint

HIV-1
RNA
Therapeutics
Risk Reduction Behavior
CD4 Lymphocyte Count
Disease Progression
Acquired Immunodeficiency Syndrome
Lymphocytes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Marschner, I. C., Collier, A. C., Coombs, R. W., D'Aquila, R. T., DeGruttola, V., Fischl, M. A., ... Saag, M. S. (1998). Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. Journal of Infectious Diseases, 177(1), 40-47.

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. / Marschner, Ian C.; Collier, Ann C.; Coombs, Robert W.; D'Aquila, Richard T.; DeGruttola, Victor; Fischl, Margaret A; Hammer, Scott M.; Hughes, Michael D.; Johnson, Victoria A.; Katzenstein, David A.; Richman, Douglas D.; Smeaton, Laura M.; Spector, Stephen A.; Saag, Michael S.

In: Journal of Infectious Diseases, Vol. 177, No. 1, 21.01.1998, p. 40-47.

Research output: Contribution to journalArticle

Marschner, IC, Collier, AC, Coombs, RW, D'Aquila, RT, DeGruttola, V, Fischl, MA, Hammer, SM, Hughes, MD, Johnson, VA, Katzenstein, DA, Richman, DD, Smeaton, LM, Spector, SA & Saag, MS 1998, 'Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy', Journal of Infectious Diseases, vol. 177, no. 1, pp. 40-47.
Marschner, Ian C. ; Collier, Ann C. ; Coombs, Robert W. ; D'Aquila, Richard T. ; DeGruttola, Victor ; Fischl, Margaret A ; Hammer, Scott M. ; Hughes, Michael D. ; Johnson, Victoria A. ; Katzenstein, David A. ; Richman, Douglas D. ; Smeaton, Laura M. ; Spector, Stephen A. ; Saag, Michael S. / Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. In: Journal of Infectious Diseases. 1998 ; Vol. 177, No. 1. pp. 40-47.
@article{5eed57ce275d409ab57760a2bd6c3886,
title = "Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy",
abstract = "Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions in plasma HIV-1 RNA levels. The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy. Pretherapy HIV-1 RNA levels were prognostic independently of on-therapy levels. In addition, the reduction in risk associated with any given reduction of the level of HIV-1 RNA did not vary by pretherapy level. Having either a reduction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a delay in clinical disease progression. This indicates that patient prognosis should be assessed using both HIV-1 RNA and CD4+ lymphocyte responses to therapy.",
author = "Marschner, {Ian C.} and Collier, {Ann C.} and Coombs, {Robert W.} and D'Aquila, {Richard T.} and Victor DeGruttola and Fischl, {Margaret A} and Hammer, {Scott M.} and Hughes, {Michael D.} and Johnson, {Victoria A.} and Katzenstein, {David A.} and Richman, {Douglas D.} and Smeaton, {Laura M.} and Spector, {Stephen A.} and Saag, {Michael S.}",
year = "1998",
month = "1",
day = "21",
language = "English",
volume = "177",
pages = "40--47",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

AU - Marschner, Ian C.

AU - Collier, Ann C.

AU - Coombs, Robert W.

AU - D'Aquila, Richard T.

AU - DeGruttola, Victor

AU - Fischl, Margaret A

AU - Hammer, Scott M.

AU - Hughes, Michael D.

AU - Johnson, Victoria A.

AU - Katzenstein, David A.

AU - Richman, Douglas D.

AU - Smeaton, Laura M.

AU - Spector, Stephen A.

AU - Saag, Michael S.

PY - 1998/1/21

Y1 - 1998/1/21

N2 - Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions in plasma HIV-1 RNA levels. The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy. Pretherapy HIV-1 RNA levels were prognostic independently of on-therapy levels. In addition, the reduction in risk associated with any given reduction of the level of HIV-1 RNA did not vary by pretherapy level. Having either a reduction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a delay in clinical disease progression. This indicates that patient prognosis should be assessed using both HIV-1 RNA and CD4+ lymphocyte responses to therapy.

AB - Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions in plasma HIV-1 RNA levels. The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy. Pretherapy HIV-1 RNA levels were prognostic independently of on-therapy levels. In addition, the reduction in risk associated with any given reduction of the level of HIV-1 RNA did not vary by pretherapy level. Having either a reduction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a delay in clinical disease progression. This indicates that patient prognosis should be assessed using both HIV-1 RNA and CD4+ lymphocyte responses to therapy.

UR - http://www.scopus.com/inward/record.url?scp=17344364659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344364659&partnerID=8YFLogxK

M3 - Article

C2 - 9419168

AN - SCOPUS:17344364659

VL - 177

SP - 40

EP - 47

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -